February 16, 2022 -- ImmunityBio has successfully acquired a leasehold interest in an International Organization for Standardization Class 5 pharmaceutical manufacturing space in western New York from global pharmaceutical company Athenex. The full-scale facility enables ImmunityBio to substantially expand and diversify its existing manufacturing capacity in the U.S. and through its strategic collaborators in Africa.
The state-of-the-art biotech production facility, located in Dunkirk, NY, includes clean rooms for upstream and downstream manufacturing activities, as well as fill and finish and large-scale lyophilization capabilities.
ImmunityBio is a clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
